Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied, under medical guidance, as potential treatments of psychiatric disorders.Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using HEK cells stably expressing 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors (5-HT 1A R, 5-HT 2A R, 5HT 2C R respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT 2A R, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT 2C R, 5-HT 1A R, and SERT. Sorting by the ratio of 5-HT 2A to 5-HT 2C , 5-HT 1A , or SERT affinity revealed chemical determinants of selectivity. We found that while 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT 2A Rs versus 5-HT 1A Rs and 5-HT 2C Rs. 5-substituted compounds exhibited high affinities for 5-HT 1A Rs, low affinities for 5-HT 2C Rs, and a range of affinities for 5-HT 2A Rs, resulting in selectivity for 5-HT 2A Rs versus 5-HT 2C Rs but not versus 5-HT 1A Rs.Additionally, a number of psychedelics bound to SERT, with non-ring substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT 2A Rs compared to 5-HT 2C Rs and 5-HT 1A Rs. Conversely,